FranΓ§aisπ See the interactive version (live chart) β
For Ensign Group, we replayed every analyst price target of the past 12 months and measured the real outcome: 71% were profitable, average return +26% (49 calls). At 3 months: +4% average return (43% profitable). The higher the %, the more often analysts were right on this stock.
Their past track record on this stock (targets replayed against real prices) β not a forecast of what will happen.
| Analyst / broker | Calls i | % profitable i | Avg return i |
|---|---|---|---|
| RBC Capital | 12 | 58% | +13% |
| Stephens & Co. | 11 | 82% | +31% |
| Oppenheimer | 9 | 89% | +29% |
Is Ensign Group overvalued, and is it a good time to buy Ensign Group right now? If you're wondering, here's a recap to make up your own mind: Ensign Group's valuation vs its sector median, to weigh alongside analyst reliability (above) and past performance. Educational information, not buy advice.
The P/E (price Γ· earnings per share) = how many years of earnings you pay for the stock. The higher it is, the more growth the market expects β but the pricier the stock, so more vulnerable if growth disappoints. The forward P/E uses next year's expected earnings: lower than the current P/E = rising expected earnings. We compare it to the sector median to see whether the stock is expensive relative to its peers.
| Metric | Ensign Group | Sector median (Health Care) |
|---|---|---|
| P/E | 28.4 | 29.4 |
| Forward P/E | 20.3 | 17.1 |
| Net margin | 7% | 12% |
π Ensign Group is valued in line with its sector (28.4 vs 29.4).
π P/E, PEG, marginβ¦: see the glossary
π΅ Dividend : Ensign Group pays about $0.26/share/yr β 0.16% yield. what is this?
The analyst consensus on Ensign Group (ENSG) is "Hold" (5 bullish, 0 bearish calls over 12 months). This is not advice: historically, 71% of their targets on this stock turned out profitable over 1 year.
The median 12-month price target is $207 (+19% vs $174), ranging from $207 to $207 (1 analysts).
Over 1 year, 71% of analyst targets on Ensign Group were profitable, for an average return of +26% (across 49 timestamped calls). This is JPI Invest's accuracy metric.
Analysts target a median of $207 within 12 months, i.e. +19% vs the current price. The most bullish targets $207, the most cautious $207.
Note: analyst targets are 12-month (median $207, +19%), NOT 2030. No reliable 5-10 year price forecast exists (Β« 2030 prediction Β» models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (71%), and the stock's past trajectory.
Its P/E is 28.4, forward P/E 20.3. A forward P/E lower than the current P/E means earnings are expected to grow.
π See the full interactive analysis of Ensign Group β
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best β on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
Explore JPI Invest for free β How it works: the method β
β οΈ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.